The prognostic value of the D-dimer test in cancer patients treated with and without low-molecular-weight heparin [2]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1531-1533

  Di Nisio, Marcelo ^a,b,c,d   Klerk, C P W ^b   Meijers, J C M ^b   Buller H R ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TUMOR MARKER; ANTICOAGULANT AGENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PLACEBO;

CANCER MORTALITY; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CANCER TEST; CANCER THERAPY; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING TEST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MORTALITY; MULTICENTER STUDY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; NADROPARIN; NEOPLASMS; PLACEBOS; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 25144516037     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01413.x     Document Type: Letter

References (11)

1. Rickles FR, Levine MN, Dvorak HF. Abnormalities in hemostasis in malignancy. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis. Philadelphia: Lippincott Williams & Wilkins, 2001: 1131-52.
2. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97: 3044-52.
3. Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 2001; 12: 51-58.
4. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prove A, Lemmens J, Vermeulen P. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-95.
5. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, Greenberg C. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004; 101: 77-82.
6. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82: 947-52.
7. Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine M. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-9.
8. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-35.
9. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-8.
10. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-71.
11. Klerk CPW, Smorenburg SM, Otten HMMB, Lensing AWA, Prins MH, Piovella F, Prandoni P, Bos MMEM, Richel DJ, van Tienhoven G, Büller HR. The effect of low-molecular-weight heparin on survival in patients with advanced malignancy. For the Malignancy and Low-molecular-weight Therapy (MALT) Investigators. J Clin Oncol 2005; 23: 2130-5.